Institute for DiagNostic Accuracy

Institute for DiagNostic Accuracy (iDNA) is a Netherlands-based healthcare and clinical research organization focused on implementing and advancing early detection of lung cancer, primarily through low-dose CT screening programs. The organization operates as a full-service CRO and research institute for screening implementation, clinical studies, imaging-AI validation, biomarker sampling, biobanking, and data management. Its core disease focus centers on lung cancer and related thoracic comorbidities, especially COPD/emphysema and cardiovascular disease. iDNA also supports decision makers, academic groups, and commercial partners with consulting, quality assurance, trial infrastructure, and software-enabled screening operations. The company appears to be service- and platform-oriented rather than a therapeutics developer, with its value proposition built around real-world screening evidence, research networks, and implementation expertise.